Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood draws could predict colon cancer treatment success

NCT ID NCT07701408

Knowledge-focused Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates whether two blood-based biomarkers—circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP)—can predict how well colon cancer responds to pre-surgery therapy. About 80 adults with stage III colon cancer will provide extra blood samples before, during, and after standard treatment and surgery. Researchers will analyze changes in these biomarkers and compare them to imaging and pathology results to see if they can forecast treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to guide colon cancer treatment, potentially reducing unnecessary surgeries or chemotherapy.
What could go wrong
This is an early-stage biomarker study with only 80 participants, so results may not be conclusive or widely applicable. The approach is observational and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older at the time of enrollment. * Histologically confirmed adenocarcinoma of the colon. * Stage III colon cancer, defined according to the applicable TNM classification based on clinical and imaging assessment. * Confirmed mismatch repair (MMR) status, determined by immunohistochemistry and/or molecular methods. * Planned neoadjuvant systemic therapy according to MMR status, followed by surgical resection with curative intent. * ECOG performance status 0-2. * Ability to understand the study and provide written informed consent. Exclusion Criteria: * Stage I, II, or IV colon cancer. * Concurrent active malignant disease, except adequately treated non-melanoma skin cancer or carcinoma in situ. * Severe comorbidities or medical conditions that prevent or substantially limit neoadjuvant systemic therapy or surgical resection. * Known autoimmune disease requiring active immunosuppressive treatment in patients with dMMR tumors. * Pregnancy or breastfeeding. * Inability or unwillingness to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Oncology Ljubljana

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.